Virginia Prepares to Legalize Psilocybin for Medical Use Pending Federal Approval
Virginia lawmakers have passed a groundbreaking law that would allow the use of psilocybin in medical treatment settings — but only after the U.S. Food and Drug Administration (FDA) gives its official approval. The measure, Senate Bill 379, directs the Virginia Board of Pharmacy to reschedule psilocybin from its current Schedule I status once federal regulators permit medical applications.
This means medical professionals in Virginia could soon administer psilocybin under strict supervision — but it will remain illegal for recreational use. The legislation was spearheaded by State Senator Jennifer Boysko, who emphasized the potential to expand crucial treatment options, particularly for veterans grappling with mental health struggles.
Why This Matters Now
The law does not change current access to psilocybin but sets the state up to move quickly if the federal government changes its stance. According to the U.S. Department of Veterans Affairs, 172 Virginia veterans died by suicide recently, underscoring the urgent need for new treatment avenues for serious mental health conditions like PTSD and depression.
“This bill is designed to give doctors more tools to save lives,” Boysko said, noting the intense toll suicide has taken on military families across the Commonwealth.
Federal Context and Virginia’s Next Steps
Currently, psilocybin remains illegal nationwide as a Schedule I drug, indicating it has no accepted medical use and a high potential for abuse. However, the federal landscape is shifting. Under the previous administration, former President Donald Trump signed an executive order urging federal agencies to speed up reviews of treatments for serious mental illnesses — including psychedelics like psilocybin.
If the FDA eventually approves a psilocybin-based treatment, Virginia’s newly minted law will allow the state to quickly implement regulations enabling medical use. Oversight of medical psilocybin administration will be under the jurisdiction of the Virginia Board of Pharmacy, ensuring treatments are safe and controlled.
A fiscal impact analysis from the Virginia Department of Planning and Budget concludes the legislation will have minimal financial impact, with costs managed within existing budgets.
What to Watch
While Senate Bill 379 officially opens the door for psilocybin as a treatment option, nothing changes today. The move hinges entirely on the FDA granting medical approval. Lawmakers and advocates across the country are watching federal decisions closely, as Virginia’s law could become a model for regulated medical use in other states if approval happens.
The Center Square was unable to obtain immediate comments from the governor’s office or Sen. Boysko before publication, but this legislation positions Virginia at the forefront of the psychedelics medical movement in the U.S.
The Human Toll Behind the Law
The rising veteran suicide rate in Virginia highlights the critical pressure on lawmakers to embrace innovative, evidence-based mental health treatments. Advocates for psilocybin research argue that psychedelic-assisted therapies might offer breakthroughs where traditional methods fall short.
As this legal framework awaits federal validation, Virginia signals a willingness to explore next-generation therapies to save lives — a message resonating with military families and mental health advocates nationwide.
Stay tuned for updates as the FDA’s decisions unfold and Virginia prepares to act swiftly on medical psilocybin availability.
